Main menu

Recent Pfizer Press Releases

5/21/14 8:15am EDT
New Survey Highlights The Impact Of Menopausal Symptoms On Women In The Workplace

Key Findings Show What Many Are Doing to ‘Keep Their Cool’

A new national survey released today by Working Mother Media and Pfizer (NYSE:PFE) on the impact of menopausal symptoms on women in the workplace finds that managing menopausal symptoms in their work life is extremely or somewhat difficult for nearly half (48 percent) of working women ages 45-65 who have experienced these symptoms in the past year.

more...
5/19/14 6:41pm EDT
Statement from Pfizer Inc.

FINAL PROPOSAL TO ASTRAZENECA

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

19 May 2014

more...
5/18/14 5:03pm EDT
PFIZER MAKES FINAL PROPOSAL TO ASTRAZENECA

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

STATEMENT FROM PFIZER INC.

5/16/14 12:12pm EDT
Pfizer To Submit Palbociclib New Drug Application With FDA Based On Final Results Of PALOMA-1

Pfizer Inc. today announced that it will submit a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for palbociclib, combined with letrozole, as first-line systemic treatment of post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.

more...
5/14/14 11:10am EDT
American College of Physicians, CECity, and Pfizer collaborate to increase adult immunization rates

 

Public health initiative aims to increase unacceptably low adult vaccination rates
 

The American College of Physicians (ACP), CECity, and Pfizer Inc. (NYSE:PFE) today announced a new initiative designed to increase adult immunization rates by assisting physicians and other health care providers in strongly recommending appropriate vaccination and tracking adult immunization rates for quality measurement and improvement. The three organizations made the announcement during the annual National Adult Influenza and Immunization Summit meeting being held May 13-15 in Atlanta.

more...
5/13/14 2:05am EDT
STATEMENT FROM PFIZER INC. (“PFIZER”)

 

Pfizer’s Possible Offer for AstraZeneca plc (“AstraZeneca”) Represents Compelling Shareholder Value

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

13 MAY 2014

more...
5/12/14 6:49pm EDT
Pfizer Prices $4.5 Billion Debt Offering

 

Pfizer Inc. (NYSE:PFE) today announced the pricing of a debt offering consisting of five tranches of notes:

more...
5/9/14 10:30am EDT
Pfizer Announces Positive Phase 2 Study Results for Investigational Meningococcal B Vaccine

Pfizer Inc. (NYSE:PFE) announced today the results from two Phase 2 studies of bivalent rLP2086, Pfizer’s recombinant vaccine candidate, currently under development for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds. In both studies, bivalent rLP2086 was observed to generate bactericidal responses, a measurement of functional immune response, against diverse meningococcal serogroup B test strains following either two or three doses

more...
5/5/14 7:00am EDT
Pfizer Reports First-Quarter 2014 Results

more...
5/2/14 2:11am EDT
Pfizer Sends Letter to Rt Hon David Cameron MP Regarding Commitments If Proposed Combination with AstraZeneca is Completed

•        Establishing the combined company’s corporate and tax residence in England

•        Substantial R&D innovation hub in Cambridge to be completed

•        Key scientific leadership in the UK

•        20% of the combined company’s total R&D workforce in the UK going forward

•        Substantial commercial manufacturing facilities retained at Macclesfield

•        European Business Headquarters and European Regulatory Headquarters to be located in the UK

•        At least two AstraZeneca Board Members to join combined company’s Board

•        Board Meetings to be held in the UK as appropriate and meaningful participation in the UK commercial, economic and social community

Pfizer Chairman and Chief Executive Officer, Ian Read, today sent the following letter to the Rt Hon David Cameron MP, with respect to Pfizer’s commitment to the U.K. and its life sciences agenda following the company’s proposal made to AstraZeneca on May 2, 2014.

more...
5/2/14 2:08am EDT
Pfizer Confirms Delivery of Increased Proposal to AstraZeneca

 

·        Proposal represents a substantial premium of 32% for AstraZeneca shareholders[1]

·        Proposal represents a 39% premium to the closing price of £35.86 on 3 January 2014, being the trading day immediately prior to the date of Pfizer’s January proposal

·        AstraZeneca shareholders would receive, for each AstraZeneca share, 1.845 shares in the combined company and 1,598 pence in cash, representing an indicative value of £50.00 ($84.47) per share[2]

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

more...
5/1/14 8:00am EDT
ALO-02 Demonstrates Significant Difference In Pain Scores In Chronic Low Back Pain Patients And Lower Abuse Potential Compared To Immediate-Release Oxycodone In Recreational Opioid Users

Pfizer Inc. (NYSE:PFE) presented results today from three pivotal studies of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules).

more...
4/28/14 7:00am EDT
Pfizer Invites Investors, Analysts And Media To Join Conference Calls Discussing Possible Combination With AstraZeneca

 

Pfizer Inc. will hold analyst and investor calls to discuss its continuing interest in a possible merger transaction with AstraZeneca Plc. at 8:30 AM EDT (1:30 PM GMT) today, April 28, 2014.

more...
4/28/14 2:08am EDT
Pfizer Confirms Prior Discussions with AstraZeneca Regarding a Possible Combination and Its Continuing Interest in a Possible Merger Transaction

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

STATEMENT FROM PFIZER INC. (“PFIZER”)

POSSIBLE OFFER FOR ASTRAZENECA PLC (“ASTRAZENECA”)

more...
4/24/14 10:50am EDT
Pfizer Hosts Annual Meeting of Shareholders Declares 26-Cent Second-Quarter 2014 Dividend

The board of directors of Pfizer Inc. today declared a 26-cent second-quarter 2014 dividend on the company’s common stock, payable June 3, 2014, to shareholders of record at the close of business on May 9, 2014. The second-quarter 2014 cash dividend will be the 302nd consecutive quarterly dividend paid by Pfizer.

more...
4/22/14 8:00am EDT
Pfizer Announces Positive Top-Line Results From Two Phase 3 Trials Of Tofacitinib In Adults With Moderate-to-Severe Chronic Plaque Psoriasis

OPT Pivotal #1 and OPT Pivotal #2 Studies, Together with Three Other Phase 3 Trials, to Form Basis for Planned Psoriasis Indication Submission to Regulatory Authorities 

Pfizer Inc. (NYSE:PFE) announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis. The OPT Pivotal #1 and OPT Pivotal #2 studies showed that tofacitinib, as a 5 mg or a 10 mg dose taken as a pill twice-daily, met the primary efficacy endpoints of statistically significant superiority over placebo at Week 16 in the proportion of subjects achieving a Physician’s Global Assessment response of “clear” or “almost clear,” and the proportion of subjects achieving at least a 75% reduction in Psoriasis Area and Severity Index, two commonly used measures of efficacy in psoriasis.

more...
4/18/14 1:40pm EST
Pfizer Invites Public To Listen To Webcast Of April 24 Annual Meeting Of Shareholders

Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 24.

more...
4/14/14 7:02am EDT
Advil® Relief in Action and Josh Duhamel Celebrate National Volunteer Week with Points of Light & Kick Off a Nationwide "Relief" Tour

Pfizer Consumer Healthcare, makers of Advil® and a unit of Pfizer Inc. (NYSE:PFE), is teaming up with actor and active volunteer Josh Duhamel for the Advil® Relief in Action campaign. Through the#ReliefinAction Pledge on Facebook and a Mobile Relief Center tour making approximately 100 stops throughout the country, Advil® will relieve the tough physical pain that can come with actively volunteering.

more...
4/6/14 10:30am EST
Pfizer’s Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer

Pfizer Inc. today announced detailed results from the PALOMA-1 study, a randomized Phase 2 study of palbociclib (PD-0332991) in combination with letrozole.

more...
3/28/14 6:26pm EDT
Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium® 24HR

Today the U.S. Food and Drug Administration (FDA) approved over-the-counter Nexium® 24HR (esomeprazole 20mg) marking a key step towards providing those who suffer from frequent heartburn broader access to a brand doctors and patients have trusted for years.

more...

Pages